Ovid Therapeutics Inc.690469101US690469101007/09/2025Advisory approval of the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES84121.0000000FOR84121.000000FORGreenlight Capital Re, Ltd.G4095J109KYG4095J109407/29/2025To consider and cast a non-binding advisory vote on a resolution approving the compensation of the Company's named executive officers as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission.SECTION 14A SAY-ON-PAY VOTES4385.0000000FOR4385.000000FORWave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTES114814.0000000FOR114814.000000FORWave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES114814.0000000ONE YEAR114814.000000FORImmunovant, Inc.45258J102US45258J102508/27/2025To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES337473.0000000FOR337473.000000FORDoximity, Inc.26622P107US26622P107508/28/2025To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTES100.0000000FOR100.000000FORReplimune Group, Inc.76029N106US76029N106309/03/2025To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTES2131.0000000FOR2131.000000FORVistagen Therapeutics, Inc.92840H400US92840H400209/09/2025To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers (NEOS).SECTION 14A SAY-ON-PAY VOTES390477.0000000FOR390477.000000FORRoivant Sciences Ltd.G76279101BMG76279101709/10/2025To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES1428820.0000000AGAINST1428820.000000AGAINSTGrace Therapeutics, Inc.00439U104US00439U104309/12/2025To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES164669.0000000FOR164669.000000FORVerona Pharma Plc925050106US925050106409/24/2025To approve, on an advisory, non-binding basis, the compensation that may be paid or become payable to the Company's named executive officers in connection with the Transaction, as disclosed in the table entitled "Potential Payments to Named Executive Officers" beginning on page 70 of the proxy statement, including the associated narrative discussion, and the agreements or understandings pursuant to which such compensation may be paid or become payable.SECTION 14A SAY-ON-PAY VOTES33790.0000000FOR33790.000000FORHoward Hughes Holdings Inc.44267T102US44267T102509/30/2025Advisory vote to approve executive officer compensationSECTION 14A SAY-ON-PAY VOTES534.0000000FOR534.000000FORKalVista Pharmaceuticals, Inc.483497103US483497103210/01/2025Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES10000.0000000FOR10000.000000FORDayforce, Inc.15677J108US15677J108811/12/2025A proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to Dayforce's named executive officers in connection with the transactions contemplated by the merger agreement, including consummation of the merger.SECTION 14A SAY-ON-PAY VOTES7750.0000000FOR7750.000000FORRezolute, Inc.76200L309US76200L309611/19/2025To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Executive Compensation section of the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES771869.0000000AGAINST771869.000000AGAINSTiBio, Inc.451033708US451033708611/20/2025To approve, on an advisory, non-binding basis, the compensation of our named executive officers ("say-on-pay").SECTION 14A SAY-ON-PAY VOTES27000.0000000FOR27000.000000FORiBio, Inc.451033708US451033708611/20/2025To approve, on an advisory, non-binding basis, the frequency of future executive compensation advisory votes.SECTION 14A SAY-ON-PAY VOTES27000.0000000ONE YEAR27000.000000FORAkero Therapeutics, Inc.00973Y108US00973Y108212/02/2025To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTES69001.0000000FOR69001.000000FORMerus N.V.N5749R100NL001160626412/09/2025Non-binding advisory proposal to approve certain compensation arrangementsSECTION 14A SAY-ON-PAY VOTES68863.0000000AGAINST68863.000000AGAINSTNeuphoria Therapeutics Inc.64136E102US64136E102912/12/2025To approve (on a non-binding advisory basis) the compensation of our named executive officers as described in the accompanying materials.SECTION 14A SAY-ON-PAY VOTES2675.0000000FOR2675.000000FORNeuphoria Therapeutics Inc.64136E102US64136E102912/12/2025To approve (on a non-binding advisory basis) the frequency of holding an advisory vote on the compensation of our named executive officers in future years.SECTION 14A SAY-ON-PAY VOTES2675.0000000ONE YEAR2675.000000AGAINSTNeuphoria Therapeutics Inc.64136E102US64136E102912/12/2025The Company's proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES0.0000000Neuphoria Therapeutics Inc.64136E102US64136E102912/12/2025The Company's proposal to approve, on a non-binding advisory basis, the frequency of an advisory vote on the compensation of the Company's named executive officers in future years.SECTION 14A SAY-ON-PAY VOTES0.0000000TherapeuticsMD, Inc.88338N206US88338N206212/15/2025To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2024;SECTION 14A SAY-ON-PAY VOTES209210.0000000FOR209210.000000FORTherapeuticsMD, Inc.88338N206US88338N206212/15/2025To provide a non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTES209210.0000000ONE YEAR209210.000000FORElectronic Arts Inc.285512109US285512109912/22/2025To consider and vote on a proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the Company's named executive officers in connection with the transactions contemplated by the merger agreement, including consummation of the merger.SECTION 14A SAY-ON-PAY VOTES4936.0000000FOR4936.000000FORAstria Therapeutics, Inc.04635X102US04635X102801/21/2026To cast a vote, on a non-binding, advisory basis, to approve the Merger-related named executive officer compensation as disclosed in the table entitled "Golden Parachute Compensation" and its accompanying footnotes which is included in the section of the proxy statement entitled "The Merger-Interests of Astria's Directors and Executive Officers in the Merger," as required by Section 14A of the Securities Exchange Act of 1934, as amended, which was enacted as part of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010.SECTION 14A SAY-ON-PAY VOTES127037.0000000FOR127037.000000FORPlymouth Industrial REIT, Inc.729640102US729640102601/22/2026To approve, by a non-binding, advisory vote, the compensation that may be paid or become payable to the Company's named executive officers in connection with the transactions contemplated by the Merger Agreement; andSECTION 14A SAY-ON-PAY VOTES41065.0000000AGAINST41065.000000AGAINSTKenvue Inc.49177J102US49177J102501/29/2026To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Kenvue Inc.'s named executive officers that is based on or otherwise relates to the transactions contemplated by the Merger Agreement.SECTION 14A SAY-ON-PAY VOTES2229.0000000FOR2229.000000FORKALA BIO, Inc.483119301US483119301001/30/2026Approval of a non-binding advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES141480.0000000AGAINST141480.000000AGAINSTBrighthouse Financial, Inc.10922N103US10922N103702/12/2026To approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to Brighthouse Financial, Inc.'s named executive officers that is based on or otherwise relates to the Merger; andSECTION 14A SAY-ON-PAY VOTES77363.0000000FOR77363.000000FORLite Strategy, Inc.55279B301US55279B301502/12/2026To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES267292.0000000FOR267292.000000FORAvidity Biosciences, Inc.05370A108US05370A108802/26/2026To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement.SECTION 14A SAY-ON-PAY VOTES488531.0000000FOR488531.000000FORVentyx Biosciences, Inc.92332V107US92332V107003/03/2026To approve, on a non-binding, advisory basis, the compensation that will or may become payable by Ventyx Biosciences, Inc. to its named executive officers in connection with the merger of merger sub with and into Ventyx Biosciences, Inc.; andSECTION 14A SAY-ON-PAY VOTES412873.0000000FOR412873.000000FOREnanta Pharmaceuticals, Inc.29251M106US29251M106203/11/2026To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES10133.0000000FOR10133.000000FORVeru Inc.92536C202US92536C202603/12/2026To approve a non-binding advisory proposal on executive compensation.SECTION 14A SAY-ON-PAY VOTES35000.0000000AGAINST35000.000000AGAINSTArrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Advisory Vote to Approve Executive Compensation.SECTION 14A SAY-ON-PAY VOTES52188.0000000AGAINST52188.000000AGAINSTOpus Genetics, Inc.67577R102US67577R102304/20/2026Approval, on an advisory basis, of the compensation of the Company's named executive officersSECTION 14A SAY-ON-PAY VOTES1508118.0000000FOR1508118.000000FORPfizer Inc.717081103US717081103504/23/20262026 advisory approval of executive compensationSECTION 14A SAY-ON-PAY VOTES62400.0000000FOR62400.000000FORBiohaven Ltd.G1110E107VGG1110E107904/28/2026A non-binding advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES30875.0000000FOR30875.000000FORSanofi80105N105US80105N105404/29/2026Approve Compensation of Frederic Oudea, Chairman of the BoardSECTION 14A SAY-ON-PAY VOTES429019.0000000FOR429019.000000FORSanofi80105N105US80105N105404/29/2026Approve Compensation of Paul Hudson, CEOSECTION 14A SAY-ON-PAY VOTES429019.0000000FOR429019.000000FORBoston Scientific Corporation101137107US101137107704/30/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES10000.0000000FOR10000.000000FORGilead Sciences, Inc.375558103US375558103604/30/2026To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES629.0000000FOR629.000000FORHealthpeak Properties, Inc.42250P103US42250P103004/30/2026Approval of 2025 executive compensation on an advisory basis.SECTION 14A SAY-ON-PAY VOTES600.0000000FOR600.000000FORInspire Medical Systems, Inc.457730109US457730109004/30/2026Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES156546.0000000FOR156546.000000FORInspire Medical Systems, Inc.457730109US457730109004/30/2026Approval, on a advisory (non-binding) basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES156546.0000000ONE YEAR156546.000000FORIntuitive Surgical, Inc.46120E602US46120E602304/30/2026To approve, by advisory vote, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES1830.0000000FOR1830.000000FORLexicon Pharmaceuticals, Inc.528872302US528872302704/30/2026Advisory vote to approve the compensation paid to the Company's named executive officersSECTION 14A SAY-ON-PAY VOTES644587.0000000FOR644587.000000FORMasimo Corporation574795100US574795100305/01/2026To consider and vote on the proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Masimo's named executive officers that is based on or otherwise relates to the Merger (the "Compensation Proposal").SECTION 14A SAY-ON-PAY VOTES15000.0000000FOR15000.000000FOREli Lilly and Company532457108US532457108305/04/2026Approval, on an advisory basis, of the compensation paid to the company's named executive officers.SECTION 14A SAY-ON-PAY VOTES35.0000000FOR35.000000FORDanaher Corporation235851102US235851102805/05/2026To approve on an advisory basis the Company's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES26761.0000000FOR26761.000000FORAvantor, Inc.05352A100US05352A100705/07/2026Advisory Approval of Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTES80000.0000000FOR80000.000000FORAvantor, Inc.05352A100US05352A100705/07/2026Advisory Vote on the Frequency of Future Advisory Votes on Executive CompensationSECTION 14A SAY-ON-PAY VOTES80000.0000000ONE YEAR80000.000000FORAbivax SA00370M103US00370M103605/11/2026Approve Compensation of Sylvie Gregoire, Chairwoman of the BoardSECTION 14A SAY-ON-PAY VOTES1311529.0000000AGAINST1311529.000000AGAINSTAbivax SA00370M103US00370M103605/11/2026Approve Compensation of Marc de Garidel, CEOSECTION 14A SAY-ON-PAY VOTES1311529.0000000AGAINST1311529.000000AGAINSTCore Scientific, Inc.21874A106US21874A106005/12/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES3961.0000000AGAINST3961.000000AGAINSTAlexandria Real Estate Equities, Inc.015271109US015271109105/13/2026To cast a non-binding, advisory vote on a resolution to approve the compensation of the Company's named executive officers, as more particularly described in the accompanying Proxy Statement.SECTION 14A SAY-ON-PAY VOTES19500.0000000FOR19500.000000FORCorbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/13/2026Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES147623.0000000FOR147623.000000FORCorbus Pharmaceuticals Holdings, Inc.21833P301US21833P301005/13/2026To vote, on an advisory basis, on how often the Company will conduct an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES147623.0000000ONE YEAR147623.000000FORDelcath Systems, Inc.24661P807US24661P807705/13/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement ("Proxy Statement").SECTION 14A SAY-ON-PAY VOTES224385.0000000AGAINST224385.000000AGAINSTIndivior Pharmaceuticals, Inc.45579U109US45579U109705/13/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES70.0000000FOR70.000000FORIndivior Pharmaceuticals, Inc.45579U109US45579U109705/13/2026To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES70.0000000ONE YEAR70.000000FORInsmed Incorporated457669307US457669307505/13/2026An advisory vote on the 2025 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES3582.0000000FOR3582.000000FORVertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES9812.0000000FOR9812.000000FORProthena Corporation plcG72800108IE00B91XRN2005/14/2026To approve, in a non-binding advisory vote, the compensation of the executive officers named in the Company's Proxy Statement for the Annual General Meeting.SECTION 14A SAY-ON-PAY VOTES753455.0000000FOR753455.000000FORUltragenyx Pharmaceutical Inc.90400D108US90400D108105/14/2026Advisory (non-binding) vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES13400.0000000FOR13400.000000FORKrystal Biotech, Inc.501147102US501147102705/15/2026Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTES18523.0000000FOR18523.000000FORNurix Therapeutics, Inc.67080M103US67080M103605/15/2026To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES48010.0000000FOR48010.000000FORTeleflex Incorporated879369106US879369106905/15/2026Approval, on an advisory basis, of named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES18287.0000000FOR18287.000000FORLarimar Therapeutics, Inc.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES35030.0000000FOR35030.000000FORLarimar Therapeutics, Inc.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Preferred Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES35030.0000000ONE YEAR35030.000000FORPassage Bio, Inc.702712209US702712209905/19/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2026 Annual Meeting.SECTION 14A SAY-ON-PAY VOTES2000.0000000FOR2000.000000FORPassage Bio, Inc.702712209US702712209905/19/2026To approve, on a non-binding advisory basis, the frequency of holding future advisory votes on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES2000.0000000ONE YEAR2000.000000FORTravere Therapeutics, Inc.89422G107US89422G107605/19/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES2473.0000000FOR2473.000000FORTravere Therapeutics, Inc.89422G107US89422G107605/19/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES2473.0000000ONE YEAR2473.000000FORViking Therapeutics, Inc.92686J106US92686J106005/19/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTES43890.0000000AGAINST43890.000000AGAINSTAlkermes plcG01767105IE00B56GVS1505/20/2026To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES6540.0000000FOR6540.000000FORGeron Corporation374163103US374163103605/20/2026To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement.SECTION 14A SAY-ON-PAY VOTES150000.0000000FOR150000.000000FORInovio Pharmaceuticals, Inc.45773H409US45773H409205/20/2026To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTES1286407.0000000FOR1286407.000000FORInteger Holdings Corporation45826H109US45826H109505/20/2026To approve, in an advisory non-binding vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES8424.0000000FOR8424.000000FORRocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026A non-binding, advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTES29835.0000000FOR29835.000000FORThermo Fisher Scientific Inc.883556102US883556102305/20/2026An advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES100.0000000AGAINST100.000000AGAINSTCorcept Therapeutics Incorporated218352102US218352102805/21/2026To approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTES8000.0000000FOR8000.000000FORDianthus Therapeutics, Inc.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTES42890.0000000FOR42890.000000FORKaryopharm Therapeutics Inc.48576U205US48576U205005/21/2026To approve, on an advisory basis, the compensation of our named executive officers, as described in the proxy statement.SECTION 14A SAY-ON-PAY VOTES70836.0000000FOR70836.000000FORKenvue Inc.49177J102US49177J102505/21/2026Approve, on a non-binding advisory basis, the compensation of Kenvue Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTES2449.0000000FOR2449.000000FORNuvation Bio Inc.67080N101US67080N101905/21/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES38390.0000000FOR38390.000000FORVera Therapeutics, Inc.92337R101US92337R101405/21/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES16633.0000000FOR16633.000000FORVerastem, Inc.92337C203US92337C203505/21/2026To approve an advisory vote on the compensation of the named executive officers.SECTION 14A SAY-ON-PAY VOTES91100.0000000FOR91100.000000FORXOMA Royalty Corporation98419J206US98419J206905/21/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES769.0000000FOR769.000000FOREstablishment Labs Holdings Inc.G31249108VGG31249108405/22/2026To approve, on an advisory basis, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTES177280.0000000FOR177280.000000FORArbutus Biopharma Corporation03879J100CA03879J100305/26/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; andSECTION 14A SAY-ON-PAY VOTES1627678.0000000FOR1627678.000000FORMerck & Co., Inc.58933Y105US58933Y105505/26/2026Non-binding advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES3000.0000000FOR3000.000000FORVir Biotechnology, Inc.92764N102US92764N102805/26/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES650989.0000000FOR650989.000000FORCytokinetics, Incorporated23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES439591.0000000FOR439591.000000FORNeumora Therapeutics, Inc.640979100US640979100005/27/2026Advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES8100.0000000FOR8100.000000FORNeumora Therapeutics, Inc.640979100US640979100005/27/2026Advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES8100.0000000ONE YEAR8100.000000FORPerspective Therapeutics, Inc.46489V302US46489V302405/27/2026To approve, on a non-binding advisory basis, the frequency of advisory stockholder votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES514860.0000000ONE YEAR514860.000000FORSpyre Therapeutics, Inc.00773J202US00773J202405/27/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES293968.0000000FOR293968.000000FOREsperion Therapeutics, Inc.29664W105US29664W105305/28/2026To approve the non-binding advisory resolution on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES19299.0000000FOR19299.000000FORNeuronetics, Inc.64131A105US64131A105105/28/2026Approval, on a non-binding, advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES2088.0000000FOR2088.000000FORTeva Pharmaceutical Industries Limited881624209US881624209805/28/2026TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE OFFICERSSECTION 14A SAY-ON-PAY VOTES5995.0000000FOR5995.000000FORCoherus Oncology, Inc.19249H103US19249H103205/29/2026To vote on a non-binding, advisory basis to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).SECTION 14A SAY-ON-PAY VOTES1445.0000000FOR1445.000000FORTaysha Gene Therapies, Inc.877619106US877619106106/01/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES2524607.0000000AGAINST2524607.000000AGAINSTTaysha Gene Therapies, Inc.877619106US877619106106/01/2026To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES2524607.0000000ONE YEAR2524607.000000FORUnitedHealth Group Incorporated91324P102US91324P102106/01/2026Advisory approval of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTES5500.0000000FOR5500.000000FORBioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES13200.0000000FOR13200.000000FORBrighthouse Financial, Inc.10922N103US10922N103706/02/2026Advisory vote to approve the compensation paid to Brighthouse Financial's Named Executive OfficersSECTION 14A SAY-ON-PAY VOTES174.0000000FOR174.000000FORNewAmsterdam Pharma Company N.V.N62509109NL00150012L706/02/2026Non-binding, advisory vote to approve the 2025 compensation of named executive officers.SECTION 14A SAY-ON-PAY VOTES36767.0000000FOR36767.000000FOROruka Therapeutics, Inc.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES17966.0000000FOR17966.000000FORPTC Therapeutics, Inc.69366J200US69366J200606/02/2026Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.SECTION 14A SAY-ON-PAY VOTES200.0000000FOR200.000000FORViridian Therapeutics, Inc.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES600.0000000FOR600.000000FORViridian Therapeutics, Inc.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES600.0000000ONE YEAR600.000000FORXenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To approve, on an advisory basis, the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTES186374.0000000FOR186374.000000FORXenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTES186374.0000000ONE YEAR186374.000000FORBeam Therapeutics Inc.07373V105US07373V105206/03/2026Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES393142.0000000FOR393142.000000FORDBV Technologies SA23306J309US23306J309506/03/2026Approve Compensation of Michel de Rosen, Chairman of the BoardSECTION 14A SAY-ON-PAY VOTES877219.0000000FOR877219.000000FORDBV Technologies SA23306J309US23306J309506/03/2026Approve Compensation of Daniel Tasse, CEOSECTION 14A SAY-ON-PAY VOTES877219.0000000AGAINST877219.000000AGAINSTDenali Therapeutics Inc.24823R105US24823R105906/03/2026Advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES424965.0000000FOR424965.000000FORGlobus Medical, Inc.379577208US379577208206/03/2026Approval, on a non-binding, advisory basis, of the 2025 compensation of the company's named executive officers (the "Say-on-Pay" Vote).SECTION 14A SAY-ON-PAY VOTES15739.0000000FOR15739.000000FORKeros Therapeutics, Inc.492327101US492327101306/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement.SECTION 14A SAY-ON-PAY VOTES65983.0000000FOR65983.000000FORNeurogene Inc.64135M105US64135M105306/03/2026To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES1.0000000FOR1.000000FORNeurogene Inc.64135M105US64135M105306/03/2026To hold a non-binding advisory vote on whether future non-binding advisory votes on the compensation paid by the company to its named executive officers should be held every one, two or three years.SECTION 14A SAY-ON-PAY VOTES1.0000000ONE YEAR1.000000FORRubrik, Inc.781154109US781154109006/03/2026Advisory vote on the frequency of future advisory votes on the compensation of Rubrik, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTES4900.0000000ONE YEAR4900.000000FORAclaris Therapeutics, Inc.00461U105US00461U105106/04/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.SECTION 14A SAY-ON-PAY VOTES438.0000000AGAINST438.000000AGAINSTAmylyx Pharmaceuticals, Inc.03237H101US03237H101406/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES234499.0000000AGAINST234499.000000AGAINSTAssembly Biosciences, Inc.045396207US045396207006/04/2026Approval, on a non-binding advisory basis, of our named executive officers' compensation.SECTION 14A SAY-ON-PAY VOTES6704.0000000FOR6704.000000FORCapricor Therapeutics, Inc.14070B309US14070B309606/04/2026APPROVAL OF NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASISSECTION 14A SAY-ON-PAY VOTES21097.0000000FOR21097.000000FORCapricor Therapeutics, Inc.14070B309US14070B309606/04/2026APPROVAL OF FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION, ONA NON-BINDING ADVISORY BASISSECTION 14A SAY-ON-PAY VOTES21097.0000000ONE YEAR21097.000000FORCG Oncology, Inc.156944100US156944100906/04/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES64147.0000000FOR64147.000000FORCG Oncology, Inc.156944100US156944100906/04/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES64147.0000000ONE YEAR64147.000000FOREdgewise Therapeutics, Inc.28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES60398.0000000FOR60398.000000FORGossamer Bio, Inc.38341P102US38341P102106/04/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES92931.0000000FOR92931.000000FORIonis Pharmaceuticals, Inc.462222100US462222100406/04/2026To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES18358.0000000FOR18358.000000FORKura Oncology, Inc.50127T109US50127T109706/04/2026Approval, on an advisory basis, of the compensation of our named executive officers ("Say-on-Pay"), as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES40000.0000000FOR40000.000000FORKura Oncology, Inc.50127T109US50127T109706/04/2026Indication, on an advisory basis, of the preferred frequency of holding future Say-on-Pay votes on executive compensation.SECTION 14A SAY-ON-PAY VOTES40000.0000000ONE YEAR40000.000000FORMoonLake Immunotherapeutics61559X104KY61559X104506/04/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES276224.0000000FOR276224.000000FORNektar Therapeutics640268306US640268306306/04/2026To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).SECTION 14A SAY-ON-PAY VOTES43015.0000000FOR43015.000000FOROrthoPediatrics Corp.68752L100US68752L100806/04/2026To approve, on an advisory basis, the compensation of our executive officers who are named in the compensation disclosures in this proxy statement.SECTION 14A SAY-ON-PAY VOTES483.0000000AGAINST483.000000AGAINSTPMV Pharmaceuticals, Inc.69353Y103US69353Y103806/04/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES231008.0000000FOR231008.000000FORPulmonx Corporation745848101US745848101406/04/2026To conduct a non-binding advisory vote to approve our executive compensation.SECTION 14A SAY-ON-PAY VOTES366302.0000000AGAINST366302.000000AGAINSTSarepta Therapeutics, Inc.803607100US803607100406/04/2026Advisory vote to approve, on a non-binding basis, named executive officer compensationSECTION 14A SAY-ON-PAY VOTES74222.0000000AGAINST74222.000000AGAINSTSavara Inc.805111101US805111101606/04/2026To approve, on an advisory basis, the compensation of our named executives.SECTION 14A SAY-ON-PAY VOTES600038.0000000FOR600038.000000FORScholar Rock Holding Corporation80706P103US80706P103006/04/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES19030.0000000AGAINST19030.000000AGAINSTSI-BONE, Inc.825704109US825704109006/04/2026Advisory vote to approve executive compensation "Say-on-Pay".SECTION 14A SAY-ON-PAY VOTES11594.0000000FOR11594.000000FORTango Therapeutics, Inc.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES21295.0000000FOR21295.000000FORDyne Therapeutics, Inc.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES47463.0000000FOR47463.000000FORSurgery Partners, Inc.86881A100US86881A100706/05/2026Approval, on an advisory basis, of the compensation paid by the Company to its named executive officers.SECTION 14A SAY-ON-PAY VOTES3124.0000000FOR3124.000000FORSutro Biopharma, Inc.869367201US869367201106/05/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES305293.0000000FOR305293.000000FORTectonic Therapeutic, Inc.878972108US878972108606/08/2026Advisory approval of the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES626.0000000FOR626.000000FORBiogen Inc.09062X103US09062X103706/09/2026Say on Pay - To hold an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES2642.0000000FOR2642.000000FORCogent Biosciences, Inc.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES700.0000000FOR700.000000FOREnliven Therapeutics, Inc.29337E102US29337E102906/09/2026To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.SECTION 14A SAY-ON-PAY VOTES240460.0000000FOR240460.000000FOREnliven Therapeutics, Inc.29337E102US29337E102906/09/2026To approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES240460.0000000ONE YEAR240460.000000FORIntellia Therapeutics, Inc.45826J105US45826J105106/09/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES15837.0000000AGAINST15837.000000AGAINSTOrganon & Co.68622V106US68622V106106/09/2026Approve, on a non-binding advisory basis, the compensation of Organon's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES3279.0000000FOR3279.000000FORPrelude Therapeutics Incorporated74065P101US74065P101206/09/2026Advisory vote to approve the 2025 compensation for the company's named executive officers (say-on-pay).SECTION 14A SAY-ON-PAY VOTES152825.0000000FOR152825.000000FORPrelude Therapeutics Incorporated74065P101US74065P101206/09/2026Advisory vote on the frequency of advisory votes on named executive officer compensation (say-on-frequency).SECTION 14A SAY-ON-PAY VOTES152825.0000000ONE YEAR152825.000000FORVoyager Therapeutics, Inc.92915B106US92915B106106/09/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES35000.0000000FOR35000.000000FORClover Health Investments, Corp.18914F103US18914F103006/10/2026Non-binding advisory proposal to approve the compensation paid to our named executive officers for 2025.SECTION 14A SAY-ON-PAY VOTES28276.0000000FOR28276.000000FORIovance Biotherapeutics, Inc.462260100US462260100706/10/2026To approve, by non-binding advisory vote, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTES18187.0000000AGAINST18187.000000AGAINSTIovance Biotherapeutics, Inc.462260100US462260100706/10/2026To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTES18187.0000000ONE YEAR18187.000000FORKiora Pharmaceuticals, Inc.49721T507US49721T507406/10/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES167941.0000000FOR167941.000000FORLineage Cell Therapeutics, Inc.53566P109US53566P109306/10/2026To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES3317.0000000FOR3317.000000FORMilestone Pharmaceuticals Inc.59935V107CA59935V107606/10/2026Say-on-Pay - A non-binding advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES100000.0000000FOR100000.000000FOROvid Therapeutics Inc.690469101US690469101006/10/2026Advisory approval of the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES3549089.0000000AGAINST3549089.000000AGAINSTPalisade Bio, Inc.696389402US696389402606/10/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES1933037.0000000AGAINST1933037.000000AGAINSTPraxis Precision Medicines, Inc.74006W207US74006W207006/10/2026To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTES55.0000000FOR55.000000FORSolid Biosciences Inc.83422E204US83422E204606/10/2026The approval of an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES61.0000000AGAINST61.000000AGAINSTSummit Therapeutics Inc.86627T108US86627T108806/10/2026Approval, by a non-binding advisory vote, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES88900.0000000AGAINST88900.000000AGAINSTuniQure N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTES82120.0000000FOR82120.000000FORuniQure N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTES82120.0000000ONE YEAR82120.000000FORBeOne Medicines Ltd.07725L102US07725L102606/11/2026THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, for the fiscal year ended December 31, 2025 be and is hereby approved.SECTION 14A SAY-ON-PAY VOTES7633.0000000FOR7633.000000FORBioCryst Pharmaceuticals, Inc.09058V103US09058V103506/11/2026To hold a non-binding, advisory vote regarding executive compensation.SECTION 14A SAY-ON-PAY VOTES105000.0000000AGAINST105000.000000AGAINSTCorvus Pharmaceuticals, Inc.221015100US221015100506/11/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES32336.0000000FOR32336.000000FOREvolus, Inc.30052C107US30052C107106/11/2026Approval of, on an advisory basis, the compensation of Evolus' named executive officers.SECTION 14A SAY-ON-PAY VOTES55859.0000000FOR55859.000000FORJanux Therapeutics, Inc.47103J105US47103J105106/11/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES174014.0000000FOR174014.000000FORNatera, Inc.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES519.0000000FOR519.000000FORNatera, Inc.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES519.0000000ONE YEAR519.000000FORPliant Therapeutics, Inc.729139105US729139105706/11/2026To approve, by non-binding advisory vote, the resolution approving Named Executive Officer compensation.SECTION 14A SAY-ON-PAY VOTES2584468.0000000AGAINST2584468.000000AGAINSTQuince Therapeutics, Inc.22053A305US22053A305906/11/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES10.0000000FOR10.000000FORWhitehawk Therapeutics, Inc.00032Q104US00032Q104006/11/2026To approve, on an advisory basis, the compensation of the named executive officers identified in the 2025 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.SECTION 14A SAY-ON-PAY VOTES105548.0000000FOR105548.000000FORKyntra Bio, Inc.31572Q881US31572Q881406/12/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES10469.0000000FOR10469.000000FORProtara Therapeutics, Inc.74365U107US74365U107906/12/2026Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTES457544.0000000FOR457544.000000FORProtara Therapeutics, Inc.74365U107US74365U107906/12/2026Vote, on an advisory basis, as to whether the stockholder advisory vote to approve the compensation of our named executive officers, (i.e., Proposal 3) should occur every one, two or three yearsSECTION 14A SAY-ON-PAY VOTES457544.0000000ONE YEAR457544.000000FORRegeneron Pharmaceuticals, Inc.75886F107US75886F107506/12/2026Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES3413.0000000FOR3413.000000FORWW International, Inc.98262P200US98262P200206/12/2026To approve, on an advisory basis, the Company's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES31946.0000000FOR31946.000000FORMirum Pharmaceuticals, Inc.604749101US604749101306/15/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES1200.0000000FOR1200.000000FORVaxcyte, Inc.92243G108US92243G108506/15/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES47160.0000000FOR47160.000000FORArdelyx, Inc.039697107US039697107106/16/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay");SECTION 14A SAY-ON-PAY VOTES23900.0000000FOR23900.000000FORArdelyx, Inc.039697107US039697107106/16/2026To approve, on a non-binding, advisory basis, whether a Say-on-Pay vote should occur every one (1) year, every two (2) years or every three (3) years;SECTION 14A SAY-ON-PAY VOTES23900.0000000ONE YEAR23900.000000FORCullinan Therapeutics, Inc.230031106US230031106306/16/2026Proposal to vote, on an advisory basis, to approve our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES18321.0000000FOR18321.000000FORIDEAYA Biosciences, Inc.45166A102US45166A102506/16/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; andSECTION 14A SAY-ON-PAY VOTES16183.0000000FOR16183.000000FORNuvalent, Inc.670703107US670703107506/16/2026To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES4181.0000000FOR4181.000000FORRxSight, Inc.78349D107US78349D107206/16/2026To approve, on an advisory basis, the compensation of the named executive officers identified in the 2025 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.SECTION 14A SAY-ON-PAY VOTES43250.0000000FOR43250.000000FORSilence Therapeutics plc82686Q101US82686Q101306/16/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTES1099651.0000000FOR1099651.000000FORXencor, Inc.98401F105US98401F105706/16/2026Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers, as disclosed in this Proxy Statement.SECTION 14A SAY-ON-PAY VOTES40000.0000000FOR40000.000000FORZentalis Pharmaceuticals, Inc.98943L107US98943L107006/16/2026Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES125745.0000000AGAINST125745.000000AGAINST4D Molecular Therapeutics, Inc.35104E100US35104E100106/17/2026Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").SECTION 14A SAY-ON-PAY VOTES18509.0000000FOR18509.000000FORAlector, Inc.014442107US014442107206/17/2026Advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES778810.0000000FOR778810.000000FORBicycle Therapeutics Plc088786108US088786108806/17/2026To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES29689.0000000FOR29689.000000FORCytomX Therapeutics, Inc.23284F105US23284F105706/17/2026To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; andSECTION 14A SAY-ON-PAY VOTES2630102.0000000FOR2630102.000000FORCytomX Therapeutics, Inc.23284F105US23284F105706/17/2026To hold a non-binding advisory vote on the frequency of future advisory votes by stockholders on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES2630102.0000000ONE YEAR2630102.000000FORDamora Therapeutics, Inc.G2646Y104KYG2646Y104406/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTES278111.0000000FOR278111.000000FORDamora Therapeutics, Inc.G2646Y104KYG2646Y104406/17/2026To conduct an advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTES278111.0000000ONE YEAR278111.000000FORForward Air Corporation34986A104US34986A104306/17/2026To approve, on a non-binding, advisory basis, the compensation of the named executive officers (the "say on pay vote").SECTION 14A SAY-ON-PAY VOTES42078.0000000FOR42078.000000FORGitLab Inc.37637K108US37637K108806/17/2026Approve, on a non-binding advisory basis, the compensation paid by GitLab Inc. to its named executive officers.SECTION 14A SAY-ON-PAY VOTES7200.0000000FOR7200.000000FORGuardant Health, Inc.40131M109US40131M109906/17/2026Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES10000.0000000FOR10000.000000FORGuardant Health, Inc.40131M109US40131M109906/17/2026Non-binding advisory vote on the frequency of stockholder advisory votes regarding compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES10000.0000000ONE YEAR10000.000000FORMadrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTES289.0000000FOR289.000000FORProtagonist Therapeutics, Inc.74366E102US74366E102906/17/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES908483.0000000FOR908483.000000FORRecursion Pharmaceuticals, Inc.75629V104US75629V104406/17/2026Advisory vote to approve executive compensation as disclosed in the 2026 Proxy Statement.SECTION 14A SAY-ON-PAY VOTES4967.0000000AGAINST4967.000000AGAINSTThe Oncology Institute, Inc.68236X100US68236X100006/17/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES12706.0000000FOR12706.000000FORThe Oncology Institute, Inc.68236X100US68236X100006/17/2026Approval, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES12706.0000000ONE YEAR12706.000000FORZai Lab Limited98887Q104US98887Q104006/17/2026THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved.SECTION 14A SAY-ON-PAY VOTES120891.0000000AGAINST120891.000000AGAINSTAgios Pharmaceuticals, Inc.00847X104US00847X104606/18/2026To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES3536.0000000FOR3536.000000FORAllogene Therapeutics, Inc.019770106US019770106506/18/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES11247.0000000FOR11247.000000FORAllogene Therapeutics, Inc.019770106US019770106506/18/2026To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES11247.0000000ONE YEAR11247.000000FORCrinetics Pharmaceuticals, Inc.22663K107US22663K107906/18/2026To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; andSECTION 14A SAY-ON-PAY VOTES938253.0000000FOR938253.000000FORDisc Medicine, Inc.254604101US254604101106/18/2026To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES384.0000000FOR384.000000FOREyePoint, Inc.30233G209US30233G209306/18/2026To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTES2000.0000000FOR2000.000000FORNextCure, Inc.65343E207US65343E207206/18/2026Approval, on an advisory basis, of the compensation paid by Company to its named executive officers.SECTION 14A SAY-ON-PAY VOTES1750.0000000FOR1750.000000FORRevolution Medicines, Inc.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTES66934.0000000FOR66934.000000FORSupernus Pharmaceuticals, Inc.868459108US868459108906/18/2026To approve, on a non-binding basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES9847.0000000FOR9847.000000FORBridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES118862.0000000FOR118862.000000FORBridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES118862.0000000ONE YEAR118862.000000FORLeonaBio, Inc.04746L203US04746L203406/22/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES72143.0000000FOR72143.000000FORLeonaBio, Inc.04746L203US04746L203406/22/2026To approve, on an advisory basis, the frequency of future stockholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES72143.0000000ONE YEAR72143.000000AGAINSTMonopar Therapeutics Inc.61023L207US61023L207906/22/2026To approve the compensation of our named executive officers on an advisory, non-binding basis.SECTION 14A SAY-ON-PAY VOTES120714.0000000AGAINST120714.000000AGAINSTSchrodinger, Inc.80810D103US80810D103706/22/2026Approval of an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES21691.0000000FOR21691.000000FORUroGen Pharma Ltd.M96088105IL001140714006/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTES78894.0000000FOR78894.000000FORARS Pharmaceuticals, Inc.82835W108US82835W108006/24/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTES1060579.0000000AGAINST1060579.000000AGAINSTARS Pharmaceuticals, Inc.82835W108US82835W108006/24/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES1060579.0000000ONE YEAR1060579.000000FORArvinas, Inc.04335A105US04335A105106/24/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES36756.0000000FOR36756.000000FORC4 Therapeutics, Inc.12529R107US12529R107706/24/2026To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES1970.0000000FOR1970.000000FORFulcrum Therapeutics, Inc.359616109US359616109706/24/2026A non-binding advisory vote to approve the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTES1700.0000000FOR1700.000000FORRhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2026Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTES142324.0000000AGAINST142324.000000AGAINSTCelldex Therapeutics, Inc.15117B202US15117B202506/25/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES289286.0000000FOR289286.000000FORInhibikase Therapeutics, Inc.45719W205US45719W205206/26/2026to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES5696203.0000000AGAINST5696203.000000AGAINSTInhibikase Therapeutics, Inc.45719W205US45719W205206/26/2026to vote, on a non-binding, advisory basis, on the frequency of future non-binding, advisory votes on compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES5696203.0000000ONE YEAR5696203.000000FORUnited Therapeutics Corporation91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTES11.0000000FOR11.000000FORInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Mark Pruzanski, Chairman of the BoardSECTION 14A SAY-ON-PAY VOTES2880021.0000000AGAINST2880021.000000AGAINSTInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Frederic Cren, CEO until September 30, 2025SECTION 14A SAY-ON-PAY VOTES2880021.0000000AGAINST2880021.000000AGAINSTInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Andrew Obenshain, CEO from October 1, 2025SECTION 14A SAY-ON-PAY VOTES2880021.0000000AGAINST2880021.000000AGAINSTInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Pierre Broqua, Vice-CEO until June 30, 2025SECTION 14A SAY-ON-PAY VOTES2880021.0000000AGAINST2880021.000000AGAINST